Baylea N Davenport

Mar 13, 2025 | biorxiv.org | Baylea N Davenport |Alyssa Williams |Timothy R.H. Regnault |Helen Jones

AbstractFetal development in an adverse in utero environment significantly increases the risk of hypertension and cardiovascular disease. The kidneys play a pivotal role in the regulation of blood pressure and cardiovascular function, and perturbations in kidney structure and molecular profile are often demonstrated in offspring born fetal growth restricted (FGR).

Jan 14, 2025 | biorxiv.org | Baylea N Davenport |Rebecca Wilson |Alyssa Williams |Helen Jones

AbstractRoughly 10% of all pregnancies are affected by fetal growth restriction (FGR). The primary etiology of FGR is placental insufficiency: the placenta not providing the appropriate amount of nutrients and oxygen to the fetus. There is currently no treatment for FGR or placental insufficiency. Because of the placentas pivotal role in FGR and supplying nutrients to the fetus, it offers an excellent target for therapeutic intervention.

Nov 3, 2024 | biorxiv.org | Baylea N Davenport |Alyssa Williams |Timothy R.H. Regnault |Helen Jones

AbstractFetal development in an adverse in utero environment significantly increases the risk of developing metabolic diseases in later life, including dyslipidemia, non-alcoholic fatty liver diseases and diabetes. The aim of this study was to determine whether improving the in utero fetal growth environment with a placental nanoparticle gene therapy would ameliorate fetal growth restriction (FGR)-associated dysregulation of fetal hepatic lipid and glucose metabolism-related signaling pathways.

Jun 8, 2024 | biorxiv.org | Helen Jones |Baylea N Davenport |Rebecca Wilson

AbstractThe etiology of fetal growth restriction (FGR) is multifactorial, although many cases often involve placental insufficiency. Placental insufficiency is associated with inadequate trophoblast invasion resulting in high resistance to blood flow, decreased availability of nutrients, and increased hypoxia.